Nivolumab/Cabozantinib Combo Shows Lasting OS Benefit for RCC in Final Analysis
February 19th 2022In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.
Venetoclax With Acalabrutinib or Obinutuzumab Evaluated in Treatment-Naive CLL/SLL
December 12th 2021In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.
SITC Releases Immunotherapy Clinical Practice Guideline for Breast Cancer
August 23rd 2021In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.
Experts Discuss the Spearhead 1 Trial and Other ASCO Data for Sarcoma Awareness Month
July 26th 2021During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.
HER2+ Status at Diagnosis in Patients With mBC Shows More Favorable PFS Than HER2-Negative Status
July 12th 2021A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.
High BMI Negatively Impacts Survival Outcomes With Osimertinib in EGFR+ NSCLC
July 5th 2021In a retrospective analysis of patients with advanced non–small cell lung cancer and EGFR mutations treated with osimertinib, investigators found that body mass index of 25 kg/mq2 or more had a negative impact on survival outcomes.
Experts Explore Landscape Advancements for Cancer Immunotherapy Month
June 23rd 2021As numerous approvals across cancer settings and emerging approaches are explored in clinical research, new findings presented at the 2021 American Society of Clinical Oncology Annual Meeting in June continue to encourage investigators.
Neoadjuvant Anthracycline-Free Regimen Achieves pCR With Less Toxicity in HER2+ Breast Cancer
June 6th 2021Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.
ARROW Update Shows Pralsetinib Has Durable Anti-Tumor Activity in RET+ Solid Tumors
June 5th 2021In an update of the ARROW trial, pralsetinib was well tolerated and demonstrated robust and durable anti-tumor activity in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.
CLN-081 Demonstrates Anti-Tumor Activity and Safety in EGFR+ NSCLC
June 4th 2021Patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations showed promising preliminary anti-tumor activity and an acceptable safety profile across all of the doses tested in a phase 1 trial of CLN-081.
Head and Neck Cancer Trial Expands to Include Patients Who Failed Checkpoint Inhibitors
June 4th 2021The phase 2 VERSATILE-002 trial of PDS0101 in combination with pembrolizumab for patients with advanced head and neck cancer has expanded to include those who have progressed on prior treatment with checkpoint inhibitors.
More Benefit Observed With Avapritinib Than Other TKIs in Mutated GIST
May 21st 2021A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation
Experts in Ovarian Cancer Discuss Targeted Agent Combinations and Disparities in Care
May 20th 2021The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.
Prior Comorbidities Predict Risk of Treatment-Emergent Atrial Fibrillation in CLL
May 3rd 2021Roughly 4% of patients with chronic lymphocytic leukemia treated with ibrutinib may experience atrial fibrillation, but their comorbidities, rather than their CLL-related factors, predict risk of treatment-emergent AF.
Immune System Plays Important Role in CAR T Cell Responses in Glioblastoma Models
April 16th 2021Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.